<qa>  What was the goal of the first clinical phase I study?The aim of the first clinical phase I study was to establish the recommended dose for a clinical phase II study and enable further development of Foxy-5 as a first in class anti-metastatic cancer drug. The study did not see any DLTs and therefore failed to reach maximum tolerated dose MTD; no recommended phase II dose RP2D could therefore be established based on toxicity. The aim of this study is to continue to establish the safety profile of Foxy-5 in higher doses, and determine the RP2D for later stage development based on any observed DLTsMTD and further analysis of the pharmacodynamic profile of Foxy-5 to determine the biological response dose BRD. 